Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

    ... MDS patients randomized in the GFM-Len-Epo2008 clinical trial to lenalidomide or lenalidomide + EPO. Clonal evolution was analyzed ...

    Research Article last updated 04/29/2016 - 11:33am.

  2. Major news in BMT with half-match donors

    ... and the primary investigator of many UT Southwestern clinical trials related to bone marrow transplantation. Mr. Dandridge enrolled in one such UT Southwestern clinical trial , studying a therapy called AG-221, developed by Agios Pharmaceuticals ...

    Article last updated 06/14/2016 - 3:02pm.

  3. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... hematopoietic responses were observed in a recent clinical trial using eltrombopag in patients with severe aplastic anemia refractory ...

    Research Article last updated 06/20/2013 - 10:13am.

  4. Personalized medicine for MDS

    ... in myelodysplastic syndromes: wishful thinking or already clinical reality? Original ... approach, however, has not been tested in a clinical trial .  -One personalized approach for lower-risk patients with MDS ...

    Research Review last updated 05/02/2016 - 9:44am.

  5. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... the treatment or management of MDS. Of those, six clinical articles of prospective phase 2-3 study design or meta-analyses were ... agents at this time outside the context of a clinical trial . Bone Marrow ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... Reliable clinical or molecular predictors of benefit from azacitidine therapy ... whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association ...

    Research Article last updated 08/04/2014 - 8:37am.

  7. Self-injected PNH therapy on the horizon

    ... positive interim data from the first cohort in its phase Ib trial that show maintenance of complement inhibition using Coversin in healthy ... diseases, and Alexion presented the first clinical data for its own next-generation complement inhibitors. Overall, we ...

    Article last updated 07/07/2016 - 9:40am.

  8. NHLBI profiles a member of the Foundation’s patient community.

    ... of Health (NIH), asking if she could be a part of the trial. She learned that to be eligible, she first needed to be a ... as much about their disease as possible — as well as about clinical trials being conducted at the National Institutes of Health.” ...

    Article last updated 06/13/2016 - 1:51pm.

  9. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... changing MDS environment is raising new challenges in clinical trial design and defining new indications for MDS drugs. Many current ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by ... syndromes. This study is based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621). ...

    Research Article last updated 04/23/2014 - 12:26pm.